| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5734324 | Journal of Surgical Research | 2017 | 8 Pages |
Abstract
The traditional clinical markers lactate and white blood cell count were not able to differentiate AMI from nonischemic bowel. However, we found that urine I-FABP was a noninvasive biomarker with high specificity and sensitivity for accurately diagnosing AMI in patients. A noninvasive accurate tool for AMI would facilitate for a rapid treatment, while preventing unnecessary surgical interventions in high-risk patient populations.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Saad Y. PhD, Pang Y. MD, Thomas A. PhD, Rachel G. MD, PhD,